NMLSF
Restart Life Sciences Corp. is a biotechnology company, which engages in the research and development of psilocybin. It offers therapy and diagnostics for neuroinflammatory disorders. The company was founded on October 27, 2004 and is headquartered in Vancouver, Canada.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | -0.01 | $134,899 | -$82,031 |
| 2025 Q4 | -0.00 | $0 | -$325,515 |
| 2025 Q3 | -0.00 | $0 | — |
| 2025 Q2 | -0.00 | $0 | -$77,590 |
| 2025 Q1 | -0.00 | $0 | -$235,248 |
| 2024 Q4 | -0.00 | $0 | -$11,296 |
| 2024 Q3 | 0.03 | $0 | -$4,449 |
| 2024 Q2 | -0.01 | $0 | -$9,761 |